Comparative Pharmacology
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus MEPROSPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus MEPROSPAN.
BUSPIRONE HYDROCHLORIDE vs MEPROSPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, primarily in the raphe nuclei and hippocampus; also exhibits antagonist properties at presynaptic 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, resulting in decreased serotonergic activity. Additionally, it has moderate affinity for dopamine D2 receptors (antagonist) and alpha2-adrenergic receptors.
Meprobamate is a carbamate derivative that acts as a central nervous system depressant. It potentiates GABA-A receptor activity and inhibits excitatory neurotransmitter release, leading to anxiolytic, sedative, and muscle relaxant effects.
Initial dose: 7.5 mg orally twice daily; may increase by 2.5-5 mg every 2-3 days to a target dose of 15-30 mg/day in divided doses (2-3 times daily). Maximum dose: 60 mg/day divided twice daily.
Meprobamate: 400-600 mg orally 3-4 times daily, maximum 2400 mg/day.
None Documented
None Documented
2-3 hours terminal half-life; clinical context: requires multiple daily dosing (3 times daily) due to short half-life; no active metabolites prolonging effect.
Terminal elimination half-life: 15 hours. Steady state reached after 3-5 days. No active metabolites.
Renal: 29-63% (as metabolites; <1% unchanged); Fecal: 18-38%; Hepatic metabolism primarily via CYP3A4; total clearance 1.5-3.5 L/h/kg.
Renal: 70% as inactive metabolites; fecal: 20% as conjugated metabolites; biliary: 10%.
Category A/B
Category C
Anxiolytic
Anxiolytic